Talha Badar/X
Jun 16, 2025, 18:24
Talha Badar: TKI Selection Based on Mutation Profiles in CML at EHA 2025
Talha Badar, Hematology/Oncology Specialist at Mayo Clinic, shared a post on X:
“Emergence of ASXL1 and tyrosine kinase domain mutation with different TKI; imatinib, 2nd generation TKI and asciminib. Best choice of TKI with respect to mutation.”
More posts featuring EHA 2025.
-
May 23, 2026, 01:51Paula Greter: Access and Innovation in Hemophilia through ERAH2026
-
May 22, 2026, 17:30Veronica Sanchez: Do You Live with Pain after a Stroke?
-
May 22, 2026, 17:25Maxime Dely: A Simple but Powerful Indicator of Platelet Quality
-
May 22, 2026, 17:24Jim Hoffman: A New Approach to Balancing Host Defense and Tissue Protection
-
May 22, 2026, 17:22Lucia Rugeri: Advancing Multidisciplinary Care for Heavy Menstrual Bleeding in Women with Bleeding Disorders
-
May 22, 2026, 17:20Nour Al-Mozain: Optimizing PBSC Collection Through Real-Time CD34+ Monitoring
-
May 22, 2026, 16:30Buse Bor: New Publication on Therapeutic Interventions for Women with Obstetric APS
-
May 22, 2026, 16:29Danny Hsu: The Reversal Dilemma – Rethinking our approach to DOAC-associated ICH
-
May 22, 2026, 16:28Bartosz Hudzik: High Bleeding Risk Does Not Always Mean Bleeding-Risk Predominance